A next-generation positron emission tomography/computed tomography (PET/CT) system, Biograph Vision.X, reportedly offers enhanced spatial resolution and a time of flight of 178 picoseconds.
Offering technological advancements ranging from an accelerated time of flight (TOF) to artificial intelligence (AI)-enabled workflow enhancements, Siemens Healthineers showcased Biograph Vision.X, a new positron emission tomography/computed tomography (PET/CT) system at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place June 24-27 in Chicago.
One of the new system’s benefits is the Optiso Ultra Dynamic Range detector technology, which reportedly provides enhanced spatial resolution through silicon photomultipliers (SiPMs) that facilitate utilization of small (3.2 mm x 3.2 mm) lutetium oxyorthosilicate crystal elements.
Leveraging this technology, the Biograph Vision.X also offers a TOF of 178 picoseconds that bolsters patient throughput and reduces radiation exposure for patients, according to Siemens Healthineers.
“This TOF improvement translates into true increased sensitivity for better imaging performance. This level of precision is more important than ever as more physicians now use PET/CT imaging not only for diagnosis but throughout the patient care cycle – from diagnosis to therapy monitoring to post-therapy follow up,” noted James Williams, Ph.D, the head of Siemens Healthineers Molecular Imaging. “And such precision in PET/CT is invaluable in theranostics, where diagnostic and therapeutic capabilities are combined to help treat post-recurrent prostate cancer patients.”
The company added that the system leverages AIDAN intelligent imaging, an AI platform built on over 700 patented machine- and deep learning applications, to enhance radiology workflow efficiency.
Pending 510(k) clearance from the Food and Drug Administration, the Biograph Vision.X system is not commercially available at this time, according to Siemens Heathineers. The company said the new system will be available as in-field upgrade for physicians who currently utilize the Biograph Vision device.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.